Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
Perfect match: Edmonton man to receive stem cell donation from sister
on July 10, 2018 at 3:17 pm
The 25-year-old underwent six rounds of chemotherapy, but the treatment was unsuccessful and he was told he needed a stem cell transplant. His family got tested, organized donor drives in Edmonton and ... […]
Alberta man finds stem-cell donor, will undergo potentially life-saving transplant
on July 10, 2018 at 12:02 pm
After months of searching, an Alberta man battling blood cancer has found the stem-cell donor who could save his life. Bille Nguyen, 25, was diagnosed in January and learned at the end of April that c... […]
Reesearchers confine mature cells to turn them into stem cells
on July 10, 2018 at 5:23 am
The resultant lab-made cells, known as induced pluripotent stem cells (iPSCs) can then be programmed into different cell types for use in tissue repair, drug discovery and even to grow new organs for ... […]
After criss-crossing Alberta looking for a stem-cell donor for her brother, Susan Nguyen discovers she was a match all along
on July 9, 2018 at 1:50 pm
And that’s amazing.” After Bille was diagnosed and chemotherapy didn’t help, doctors informed his family that the only way the 25-year-old had any chance of survival was to do a stem-cell transplant, ... […]
Match found: Alberta sisters thrilled to find stem cell donor for brother, possibly others
on July 9, 2018 at 11:57 am
One doctor gave him a 10 per cent chance of survival, unless the 25-year-old could have a stem cell transplant this summer. Because his best bet for a match is someone of similar ethnicity, his sister... […]
Pixantrone Falls Short in Phase III B-Cell NHL Trial
on July 9, 2018 at 9:11 am
Patients had received CHOP-R or equivalent treatment and relapsed. Individuals were not eligible for stem cell transplant. Beyond the primary PFS endpoint, secondary outcome measures included overall ... […]
Teratoma-Derived Stem Cells Rebuild Muscle in Model of Muscular Dystrophy
on July 6, 2018 at 7:01 am
Pluripotent stem cells don’t differentiate spontaneously into skeletal muscle cells in vitro, and to date, generating functional, force-producing muscle tissue through cell transplantation has require... […]
Stem Cell Banking Market Size, Share, Growth, Forecast and Outlook 2025: Top Companies, Trends and Future Prospects Details for Business Development
on July 2, 2018 at 8:23 pm
Cord Stem Cell Banking market provides information of Cord blood collection and transplant has a distinct advantage over other competing alternatives such as bone marrow transplant in case of blood re... […]
Almost two thirds of Britons would not donate stem cells to loved ones, survey claims
on July 2, 2018 at 1:26 pm
... donate their stem cells – even if a loved one needed a transplant. A survey of 2,000 adults found 61 per cent could not be encouraged to donate. Four in 10 Britons say reports of stem cell and bon... […]
Most Brits WOULDN’T donate stem cells – even if their loved one needed life-saving transplant
on June 28, 2018 at 11:08 am
Four in ten Brits say reports of stem cell and bone marrow transplants being too painful put them off donating. And just 16 per cent have donated stem cells or bone marrow in the past – nearly five ti... […]
via Google News and Bing News